Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains.
PMID: 32125378
2020
The Journal of antimicrobial chemotherapy
Abstract: INI DRMs differed between B and F IN subtypes, with Q148K/R/H, G140S and E138K/A being more prevalent in subtype B (63% versus 0%, P = 0.0021; 50% versus 0%, P = 0.0096; and 50% versus 0%, P = 0.0096, respectively).
HIV-1 Drug Resistance in ART-Naive Individuals in Myanmar.
Result: The most frequently observed SDRMs were V179D/T (8.3%), E138A (4.1%) and L33F (2.4%), which are involved in the resistance to NNRTIs, NNRTIs, and PIs, respectively (Figures 2 and 3B).
Result: There were four TCs involving V179T-carrying strains, and five TCs for L33F-, L90M-, A98G-, E138A- and T215TADN-carrying strains each.
Result: Two TCs (Clusters 3 and 8) contained three individuals who carried single SDRM E138A or A98G.
Discussion: A high proport
Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.
Abstract: E138A/G/K/R (14.3%, 46/322) and V179E/D/T (13.7%, 47/322) were the predominant DRMs.
Result: The drug resistance-associated mutations are shown in Table 2, among which E138A/G/K/R (14.3%, 46/322) and V179E/D/T (13.7%, 47/322) were far higher than the others.
Table: E138A
Discussion: E138A/G/R results in low-level resistance to RPV and E138K results in intermediate-level resistance to RPV.
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Introduction: Genetic resistance pathways including primary mutations at codons Y143C/H/R, Q148H/K/R or N155H together with one or more additional associated secondary mutations at L74M, E92Q, T97A, E138E/A/K or G140S/A, has been reported to result in higher levels of resistance with RAL treatment.
Table: E138A
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Result: E138A/G/R/K/Q was found in this case and was predicted to have low/potential resistance to RPV and ETR.
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I, Y181C/V, and Y188H/C.
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
Result: E138QGA occurred in four (4%) patients receiving AZT plus 3TC, in three (3%) patients receiving ABC plus 3TC, and in one (1%) patient receiving TDF plus 3TC.
Discussion: The group receiving AZT plus 3TC or ABC plus 3TC showed the highest rates of NNRTI mutations such as P225H, V106M, E138A/G/K/Q, G190A/S, and Y188L occurred most frequently in patients receiving AZT plus 3TC or ABC plus 3TC.
Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy.
PMID: 32158555
2020
Southern African journal of HIV medicine
HIV mutation literature information.
PMID: 
2020
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT